ReviewNature reviews. Clinical oncology2024
The high costs of anticancer therapies in the USA: challenges, opportunities and progress.
Review in Nature reviews. Clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Metabolism and Immunity-Adapted Radiotherapy (M.I.A.R): A Conceptual Framework for Overcoming the Therapeutic Plateau in Clinical Radiotherapy.Current oncology (Toronto, Ont.) · 2026Review
- Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026Article
- The Enigmatic Tumor Suppressor p53 Biomolecule: Its Role and Prognostic and Predictive Values in Cancer Therapy and Precision Medicine.Biomolecules · 2026Review
- Cost-effectiveness analysis of nab-paclitaxel with or without relacorilant for platinum-resistant ovarian cancer.Journal of ovarian research · 2026Article
- Estimating US savings on outpatient prescription pharmaceuticals from international reference pricing.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Cost-Effectiveness of Tarlatamab in the Second-Line Treatment of Refractory Small Cell Lung Cancer From a US Perspective.Clinical Medicine Insights. Oncology · 2026Article
- Global disparities in access to diagnostics and therapies for advanced non-small cell lung cancer: from discovery to delivery - a review.Frontiers in oncology · 2026Review
- Ensemble machine learning for predicting costs and cost influencers in breast cancer surgery.BMC health services research · 2025Article
- Challenges and opportunities for improvement in the practical management of adults with acute lymphoblastic leukemia.Blood advances · 2025Review
- Cost-effectiveness analysis of datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer.Cost effectiveness and resource allocation : C/E · 2025Article
- Increasing the focus on critical appraisal of trials and financial conflict of interest in medical training programs: a perspective from oncology.Frontiers in medicine · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
Abstract
The USA spent $99 billion on orally administered and clinician-administered anticancer therapies (excluding supportive care) in 2023 and spending is projected to increase to $180 billion by 2028. This increased spending on anticancer therapies largely reflects the high launch prices of novel therapeutics and increases in the prices of existing products, even in the absence of new evidence of clinical benefit or changes in use. Consequently, high prices have impeded Americans' access to and affordability of necessary anticancer therapies and thus increased their risk of cost-related non-adherence, cancer recurrence and mortality. To address the rising prices and concerns regarding Americans' spending on anticancer therapies, state and federal governments have, over the past decade, enacted legislation that caps out-of-pocket spending, expands subsidies and requires drug price negotiations. In this Perspective, we summarize US policies aimed to lower the costs of anticancer therapies, discuss the implications of such reforms and propose additional solutions needed to reduce costs and increase value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.